US-based healthcare company PerkinElmer and Cerep, a provider of drug candidate screening and profiling technologies, have expanded their kinase assay offering.
Close to 200 new kinase assays validated with PerkinElmer’s Lance Ultra technology will be offered for use through Cerep’s drug candidates selection and qualification services.
Key therapeutic research pathways supported by the new 189 kinase assays include cancer, cardiac disease, central nervous system disorders, inflammation, diabetes, and metabolic disorders, amongst others.
The collaboration between the two companies first announced in April 2008 delivers custom drug discovery services, through a combination of PerkinElmer’s assay technologies, and Cerep’s target screening and drug discovery offerings.
Richard Eglen, president of bio-discovery at PerkinElmer, said: The extensive range of high quality kinase assays now available for screening and profiling through this collaboration is a compelling complement to the profiling services offered by Cerep. It provides our customers with the expansive range of products and expertise necessary for broad compound screening campaigns to aid their research.
Our clients can now benefit from testing their compounds against a broad range of kinase targets via a single platform, validated for performance with PerkinElmer’s innovative Lance Ultra portfolio and diversified Ulight substrates, for consistently high quality results.